JPRN-UMIN000015877已完成1 期
PhaseI/II study of irinotecan and oxaliplatin combination chemotherapy in patients with gemcitabine and 5-fluorouracil refractory pancreatic cancer. - PhaseI/II study of IROX therapy in gemcitabine and 5-fluorouracil refractory pancreatic cancer.
Chiba cancer center0 个研究点目标入组 30 人开始时间: 2014年12月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Severe complications. (2)Grade2 or greater peripheral neuropathy. (3)Patients who received blood transfusions or hematopoietic growth factors within 7 days before the laboratory test (4)Active infections. (5)Pulmonary fibrosis or interstitial pneumonia. (6)Clinically evident pleural, abdominal or cardiac effusion. (7)Watery diarrhea within 3days before registration. (8)Surgery within 4weeks,chemotherapy within 2 weeks,radiation therapy within 2 weeks. (9)Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies. (10)Poorly controlled diabetes. (11)Brain metastasis. (12)Severe mental disorder. (13)Double advanced cancer. (14)Severe drug allergies. (15)pregnant or lactating female. (16)Current use atazanavir. (17)Concurrent chronic systemic steroid treatment. (18)Having UGT1A1*6/*6,UGT1A1*28/*28 or UGT1A1*6/*28 gene (19)Prior therapy with irinotecan or oxaliplatin. (20)Inappropriate for entry onto the study,as diagnosed by primary physician.
研究者
相似试验
已完成
不适用
Phase I study of irinotecan, S-1 and oxaliplatin in combination with radiation therapy in patients with advanced rectal canceradvanced rectal cancerJPRN-UMIN000017674Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine12
进行中（未招募）
不适用
Phase II study of Oxaliplatin / Irinotecan / Cetuximab as first line therapy in locally advanced or metastatic gastric cancerPatients with histologically proven inoperable locally advanced or metastatic gastric cancerEUCTR2006-001989-16-ATAGMT
进行中（未招募）
1 期
Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patientsnresectable locally advanced or metastatic Gastric CancerMedDRA version: 20.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006128-79-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH40
进行中（未招募）
2 期
Phase2 trial of oxaliplatin, irinotecan and S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancerpancreatic cancerJPRN-jRCTs011190008Komatsu Yoshito40
已完成
不适用
Phase I study of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with limited-disease small cell lung cancerCancerLung CancerISRCTN75771514Erasmus Medical Centre (The Netherlands)9